key: cord-0855976-ftmtt5tj
authors: Bordry, Natacha; Addeo, Alfredo; Jaksic, Cyril; Dutoit, Valérie; Roux-Lombard, Pascale; Shah, Dimpy P.; Shah, Pankil K.; Gayet-Ageron, Angèle; Friedlaender, Alex; Bugeia, Sébastien; Gutknecht, Garance; Battagin, Anna; Di Marco, Maragrazia; Simand, Pierre-Francois; Ladibi-Galy, Intidhar; Fertani, Sarah; Sandoval, José; Dietrich, Pierre-Yves; Mach, Nicolas
title: Humoral and Cellular Immunogenicity two months after SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer
date: 2021-12-24
journal: iScience
DOI: 10.1016/j.isci.2021.103699
sha: f3d028f00425c2beab94de2f939f0bb5eee705ac
doc_id: 855976
cord_uid: ftmtt5tj

Little is known on the long-lasting humoral response and the T cell activation induced by SARS-COV2 mRNA vaccines in patients with cancer. The study assessed the efficacy of the SARS-COV2 mRNA vaccines through measuring the seroconversion rate at pre-specified time points and the effect on the T cell immunity in patients with cancers. The study included 131 adult patients with solid or haematological cancer, who received SARS-COV2 mRNA vaccines. 96.2% of them exhibited adequate antibody response to the SARS-COV2 mRNA vaccines 2 months after the booster dose. SARS-COV2 mRNA vaccines could induce T cell activation, however this is more likely in patients who have a positive seroconversion (94%) compared to the patients who did not (50%). Further research into the clinical relevance of low antibodies titers and lack of T cell activity is required to set up an effective vaccination strategy within this group of patients.

Messenger RNA (mRNA)-based vaccines have changed the outlook of the COVID-19 pandemic (Regev-Yochay et al., 2021) . However, clinical trials leading to regulatory authority approval of these vaccines included very few patients with cancer, and patients on active therapy were excluded (Polack et al., 2020) .

Several studies in patients with solid and haematological malignancies (Addeo et al., 2021; Goshen-Lago et al., 2021; Thakkar et al., 2021) have shown that the seroconversion rate, at a minimum of 3 weeks after the second dose, ranged from 90-95% in patients with solid tumours and 70%-75% in patients with haematological malignancy (Polack et al., 2020; Voysey et al., 2021) . Studies of acute and convalescent COVID-19 patients highlighted that SARS-CoV-2-specific T cell responses are significantly associated with milder disease (Grifoni et al., 2020; Sekine et al., 2020) .

Here, we report data on humoral immune responses after SARS-CoV-2 mRNA vaccination among patients with solid and haematological malignancy. We measured seroconversion rates and antibody titers 60 days after the booster dose, as well as T cell responses in two pre-specified cohorts of patients.

We recruited 131 patients with cancer who received either BNT162b2 or mRNA-1273 vaccines at the Geneva University Hospital (HUG). All patients were SARS-CoV-2 naïve, as determined by a negative anti-SARS-CoV-2 nucleocapsid (N) protein IgG test at baseline. One patient developed COVID-19 4 weeks after the second dose.

That patient did not show any seroconversion at T2 and was on anti-CD20 treatment.

Thus, 130 patients were included in the final analysis. within 6 months prior to COVD-19 vaccination. The most common anti-cancer therapy received by this cohort of patients was cytotoxic chemotherapy (27.7%), followed by kinase inhibitors (11%), endocrine therapy (10.8%), immunotherapy (8.5%), chimioimmunotherapy (6.9%), monoclonal antibody (3.8%) and anti-CD20 therapy (1.5%). There was no statistically significant difference in the seroconversion rates by gender, age, vaccine, or tumour stage ( Table 1 ). The seroconversion rate was 93% (121/130) at T2 and rose to 96.2% (125/130) at T3. Among the 9 patients who were seronegative at T2, 4 (44.4%) showed spontaneous seroconversion at T3 without any sign of contact with SARS-CoV-2, as anti-N IgG remained undetectable.

The seroconversion rate was significantly lower in patients with haematological malignancy, 73.9% (17/23) at T2 and 82.6% (19/23) at T3 as compared to 97.2 (104/107) and 99.1% (106/107) in patients with solid tumours (p=0.009 and 0.02, respectively). Only 1 out of 2 patients receiving anti-CD20 therapy (50%) produced anti-S IgG antibodies at T3. Other treatments, including chemotherapy, endocrine therapy, or immunotherapy (immune checkpoint inhibitors), had no discernible impact on the seropositivity rate at T3.

We then measured T cell activity, by positive IFN- levels, in two pre-specified cohorts of patients. Cohort 1 consisting of patients who did not seroconvert 3-4 weeks after second vaccine dose (T2) (n=9) and cohort 2 consisting of patients who had the highest antibody titers at T2 (n=18). T cell activity was detected in 4/9 patients (44.6%) within cohort 1 at T3. Within cohort 2, 17 / 18 patients (94.4%) showed T cell activation at T3 through a strong QuantiFERON signal ( Figure 1 ). Higher QuantiFERON values were seen in haematological patients once compared to solid cancer patients although this difference was not significant (p=0.664) ( Figure 2 ).

We showed high humoral immune response to mRNA SARS-CoV-2 vaccines among patients with solid and haematological malignancies even at 60 day from the second dose. Solid tumours were associated with significantly higher seroconversion rates than haematological malignancies at T2 and T3. The study showed that the seroconversion rate increased from 93.1% (T2) to 96.1% at T3 highlighting that mRNA vaccines can induce rapid and delayed durable seroconversion.

Within our study T cell activation occurred in the vast majority of the cases (77.7%), more frequently in patients who had high anti-S IgG titer level (94.5%) compared to patients who had no antibodies or seroconverted at T3 (44.6%) Furthermore, despite the fact that the delta SARS-COV-2 variant has become predominant in Geneva, only 1 patient within our study group (1/131) was infected and had mild COVID-19.

In conclusion, our data show that seroconversion rates remain high 60 days after the second vaccine dose in patients with cancer, that T cell activation is present in most of cases and that the level of protection remains very high (only 1 case of COVID-19 in the whole study group). Given the recent FDA and EMA authorization for third doses in immunocompromised patients, we believe more data on the relevance and impact of cellular immunity are warranted to set up new guidance on vaccination strategies for patients with cancer.

Despite these strengths, the present study had several limitations. Firstly, one of the possible limitations might be how to interpret the anti-S-IgG antibodies level and T cells activity and degree of protection they could offer to patient with cancers. We have no clear data so far to claim that patients with higher antibodies level are more protected than the others and whether a certain cut-off should be used, for example, to consider a third dose of vaccine. Equally we have no data to claim that T cell activation on its own could offer a real protection from SARS-COV-2 infection.

However, only 1 patient out of 131 (0, 76%) in our fully vaccinated patients got mild COVID-19.

Secondly, the sample size of the seronegative cohort (patient who did not develop any SARS-COV2 IgG antibody) in our study is relatively small due to the efficacy of the vaccines. T cell response has therefore been evaluated on a small subgroup of patients.

Finally, the SARS-CoV-2 specific T cell assay has not yet been approved for clinical use but it provides reliable data on the T cell response although it does not evaluate the full T cell repertoire.

Larger validation prospective cohort studies assessing humoral and cellular immunity on non-vaccine responders are needed.

J o u r n a l P r e -p r o o f

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Alfredo Addeo, alfredo.addeo@hcuge.ch.

This study did not generate new unique reagents.

The published article includes all data generated and analysed during this study.

Data will be made available freely from the corresponding authors upon request.

All analyses were conducted with built-in and freely available R packages.

This study was approved by institutional review board. We performed a prospective observational study on patients with cancer who received mRNA-1273 or Data on humoral activity at T1 and T2 were previously reported and published.

Here we report the data on seroconversion at T3 and the data about T cellular active in 2 pre-specified cohorts at T3. These samples were tested for both anti-SARS-CoV-2 spike (S) IgG and nucleocapsid (N) IgG titers. The samples at T3 were tested for

The current study has two primary outcomes: 1) rates of seroconversion to the SARS-CoV-2 S protein at T3; and 2) Level of T cell activation in 2 pre-specified cohorts (Cohort 1 that includes patients who didn't show any seroconversion at T2 and cohort 2 that includes patients who showed high antibody level at T2).

Blood samples collected using standard sampling tubes were directly centrifuged, and serum was stored at -80°C until batch analysis. The immunogenicity of mRNA vaccines was assessed by Elecsys® Anti-SARS-CoV-2S immunoassay for the in vitro and are considered as positive when equal to or above 1.

All patients who did not have a positive seroconversion (anti-IgS IgG titers <0.8 U/ml) at T2 (9/130 patients) were identified and tested on T3 for T cell immunity through QuantiFERON analysis as part of cohort 1. We used as a control group (cohort 2) 18 patients who showed high antibody titers at T2 with anti-IgS IgG titers above 2000U/ml). They were identified and subsequently tested at T3 for T cell immunity through QuantiFERON analysis. SARS-CoV-2-specific T cell responses were assessed by QuantiFERON ELISA (Qiagen, Hilden, Germany) which is a whole blood Interferon-Gamma Release immuno Assay (IGRA) that uses two combinations of specific peptides from the spike antigen (S1, S2, RBD subdomains) eliciting CD4+ (COVT1) and CD4+ and CD8+ (COVT2) T cell responses. The performance of this assay has been internally tested and validated using clinical and biological criteria for control (no prior SARS-COV 2 infection and no vaccination received) and vaccinated patient cohorts (Jaganathan S. et al., Infect. Dis. Ther. 2021).

Briefly, venous blood samples were collected directly into the QuantiFERON® tubes containing Spike peptides as well as positive and negative controls (626715 QFN SARS-CoV-2 Starter Pack). Whole blood was incubated at 37°C for 16-24 hours and centrifuged to separate plasma. IFN-γ (IU/ml) was measured in these plasma samples using ELISA (626410 QuantiFERON ELISA, Human IFN-γ SARS-CoV-2, Qiagen) tests. A cut-off value of 0.15 IU/mL was used to discriminate positive from negative 

Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. The Lancet Regional Health

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease-the impact of diagnosis and cancer-directed therapies. medRxiv

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK